Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides

Patients with cutaneous T-cell lymphoma (CTCL) who have cutaneous tumors or folliculotropic disease involvement typically have poor prognoses. Analysis of the pivotal phase 2 trial of romidepsin in relapsed/refractory CTCL showed that single-agent romidepsin induced clinical response or stable disease in the majority of patients with cutaneous tumors and/or folliculotropic disease involvement, supporting its use in these patient populations.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research